Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Zoledronic acid
Drug ID BADD_D02392
Description Zoledronic acid, or CGP 42'446,[A203120] is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid].[A203111] Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.[L13712,L13715,L13721] Zoledronic acid was first described in the literature in 1994.[A203120] Zoledronic acid was granted FDA approval on 20 August 2001.[L13712]
Indications and Usage Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women.[L13712,L13715,L13721] Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.[L13712,L13715,L13721]
Marketing Status approved
ATC Code M05BA08
DrugBank ID DB00399
KEGG ID D01968; D08689
MeSH ID D000077211
PubChem ID 68740
TTD Drug ID D0VM2L
NDC Product Code 63415-0532; 0078-0435; 25021-826; 55150-266; 67457-619; 68083-142; 14593-836; 63850-7104; 82920-012; 63323-966; 69367-190; 65372-1117; 17478-327; 71288-806; 62147-0125; 68554-0037; 16729-242; 43598-330; 55150-283; 67457-794; 68001-437; 65129-1144; 0143-9642; 63323-961; 68083-116; 68083-135; 0409-4215; 16714-815; 67457-390; 68083-256; 63126-906; 43598-331; 70860-210; 72266-152; 42533-102; 53104-7622; 65797-0006; 43598-255; 25021-801; 54288-100; 57741-2600; 25021-830; 55111-685; 55111-688
UNII 6XC1PAD3KF
Synonyms Zoledronic Acid | 2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid | CGP 42446A | CGP-42446 | CGP 42446 | CGP42446 | CGP-42'446 | CGP42'446 | CGP 42'446 | Zometa | Zoledronic Acid Anhydrous | Zoledronate
Chemical Information
Molecular Formula C5H10N2O7P2
CAS Registry Number 118072-93-8
SMILES C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Arteriosclerosis24.04.02.0010.004294%Not Available
Arthralgia15.01.02.0010.559700%
Arthritis15.01.01.0010.036073%
Arthropathy15.01.01.0030.013456%Not Available
Asthenia08.01.01.0010.141142%Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atelectasis22.01.02.0010.002863%
Atrial fibrillation02.03.03.002--
Atrial flutter02.03.03.0030.006298%
Atrioventricular block02.03.01.002--Not Available
Atrioventricular block complete02.03.01.0030.002863%
Atrophy08.03.04.001--Not Available
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.010--Not Available
Azotaemia20.01.01.001--Not Available
B-cell lymphoma01.15.01.001; 16.28.01.001--Not Available
Back disorder15.03.05.0030.002863%Not Available
Back pain15.03.04.0050.193533%
Bladder cancer20.03.04.001; 16.08.01.001--Not Available
Blindness06.02.10.003; 17.17.01.0030.017178%Not Available
Blindness transient06.02.10.006; 17.17.01.0040.002863%Not Available
Blindness unilateral06.02.10.007; 17.17.01.0160.007157%Not Available
Blood calcium decreased13.11.01.002--Not Available
Blood creatinine abnormal13.13.01.002--Not Available
Blood creatinine decreased13.13.01.003--Not Available
Blood creatinine increased13.13.01.004--
Blood urea increased13.13.01.006--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.0040.041512%Not Available
Bone neoplasm16.29.01.001; 15.09.02.001--Not Available
Bone pain15.02.01.0010.308336%
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 26 Pages